IL5 and eosinophilic esophagitis: The anti-IL-5 antibodies, mepolizumab and reslizumab, bind to IL-5 and are also able to mitigate eosinophilic esophagitis through the prevention of IL-5 signaling, reducing the production and survival of eosinophils [135].